{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T21:14:19Z","timestamp":1648847659629},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Therapeutic Goods Administration"},{"DOI":"10.13039\/501100002873","name":"Chulalongkorn University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002873","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regulatory Toxicology and Pharmacology"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.yrtph.2014.10.013","type":"journal-article","created":{"date-parts":[[2014,10,27]],"date-time":"2014-10-27T18:32:23Z","timestamp":1414434743000},"page":"108-113","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["An analysis of legal warnings after drug approval in Thailand"],"prefix":"10.1016","volume":"71","author":[{"given":"Pakawadee","family":"Sriphiromya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anuchai","family":"Theeraroungchaisri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.yrtph.2014.10.013_b0005","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1001\/archinternmed.2010.91","article-title":"Coverage of FDA medication boxed warnings in commonly used drug information resources","volume":"170","author":"Cheng","year":"2010","journal-title":"Arch. Intern. Med."},{"issue":"11","key":"10.1016\/j.yrtph.2014.10.013_b0010","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2165\/11316670-000000000-00000","article-title":"Risk management policy and black-box warnings","volume":"32","author":"Cook","year":"2009","journal-title":"Drug Saf."},{"issue":"6","key":"10.1016\/j.yrtph.2014.10.013_b0015","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0890-6238(01)00178-2","article-title":"The teratogenic risk of trimethoprim\u2013sulfonamides: a population based case\u2013control study","volume":"15","author":"Czeizel","year":"2001","journal-title":"Reprod. Toxicol."},{"issue":"4","key":"10.1016\/j.yrtph.2014.10.013_b0020","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/ajg.2011.449","article-title":"How the FDA manages drug safety with black box warnings, use restrictions, and drug removal, with attention to gastrointestinal medications","volume":"107","author":"Ehrenpreis","year":"2012","journal-title":"Am. J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.yrtph.2014.10.013_b0025","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1177\/009286150103500134","article-title":"Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets-1960\u20131999","volume":"35","author":"Fung","year":"2001","journal-title":"Drug Inform. J."},{"issue":"Suppl. 1","key":"10.1016\/j.yrtph.2014.10.013_b0030","first-page":"s1","article-title":"Pharmacovigilance and drug safety 2011 in Calabria (Italy): adverse events analysis","volume":"4","author":"Giofr\u00e8","year":"2013","journal-title":"J. Pharmacol. Pharmacother."},{"issue":"4","key":"10.1016\/j.yrtph.2014.10.013_b0035","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S1550-8579(06)80214-7","article-title":"Estrogen replacement in menopausal women: recent and current prospective studies, the WHI and the KEEPS","volume":"3","author":"Harman","year":"2006","journal-title":"Gend. Med."},{"issue":"4","key":"10.1016\/j.yrtph.2014.10.013_b0040","first-page":"423","article-title":"Selective COX-2 inhibitors and risk of thromboembolic events-regulatory aspects","volume":"96","author":"Heim","year":"2006","journal-title":"Thromb. Haemost. Stuttg."},{"issue":"1","key":"10.1016\/j.yrtph.2014.10.013_b0045","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s40290-013-0006-6","article-title":"A descriptive study of additional risk minimization measures included in risk management plans reviewed by the United Kingdom regulatory authority","volume":"27","author":"Keddie","year":"2013","journal-title":"Pharm. Med."},{"issue":"2","key":"10.1016\/j.yrtph.2014.10.013_b0050","doi-asserted-by":"crossref","first-page":"S126","DOI":"10.1016\/j.jaci.2009.10.028","article-title":"Drug allergy","volume":"125","author":"Khan","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"issue":"3","key":"10.1016\/j.yrtph.2014.10.013_b0055","doi-asserted-by":"crossref","first-page":"242","DOI":"10.4103\/0022-3859.41819","article-title":"Nimesulide and adverse drug reactions: time for a database","volume":"54","author":"Khan","year":"2008","journal-title":"J. Postgrad. Med."},{"issue":"17","key":"10.1016\/j.yrtph.2014.10.013_b0060","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1001\/jama.287.17.2215","article-title":"Timing of new black box warnings and withdrawals for prescription medications","volume":"287","author":"Lasser","year":"2002","journal-title":"JAMA, J. Am. Med. Assoc."},{"key":"10.1016\/j.yrtph.2014.10.013_b0065","unstructured":"Lemery, R. L., 2012. Signal Prioritization."},{"issue":"5","key":"10.1016\/j.yrtph.2014.10.013_b0070","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1053\/j.ajkd.2010.07.011","article-title":"Severe rhabdomyolysis as a consequence of the interaction of fusidic acid and atorvastatin","volume":"56","author":"Magee","year":"2010","journal-title":"Am. J. Kidney Dis."},{"issue":"8","key":"10.1016\/j.yrtph.2014.10.013_b0075","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2165\/00002018-200427080-00002","article-title":"Risk management from an Asian\/Pacific rim regulatory perspective","volume":"27","author":"McEwen","year":"2004","journal-title":"Drug Saf."},{"issue":"1","key":"10.1016\/j.yrtph.2014.10.013_b0080","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jaci.2005.10.031","article-title":"\u201cBlack box\u201d 101: how the Food and Drug Administration evaluates, communicates, and manages drug benefit\/risk","volume":"117","author":"Murphy","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"issue":"7","key":"10.1016\/j.yrtph.2014.10.013_b0085","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1007\/s00125-012-2538-9","article-title":"Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study","volume":"55","author":"Neumann","year":"2012","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.yrtph.2014.10.013_b0090","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1046\/j.1365-2036.2001.00962.x","article-title":"Population-based case control study of the safety of sulfasalazine use during pregnancy","volume":"15","author":"N\u00f8rg\u00e5rd","year":"2001","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.yrtph.2014.10.013_b0095","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s11606-011-1633-9","article-title":"Different black box warning labeling for same-class drugs","volume":"26","author":"Panagiotou","year":"2011","journal-title":"J. Gen. Intern. Med."},{"issue":"1","key":"10.1016\/j.yrtph.2014.10.013_b0100","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11882-002-0033-y","article-title":"Allergic adverse reactions to sulfonamides","volume":"2","author":"Vial","year":"2002","journal-title":"Curr. Allergy Asthma Rep."},{"issue":"6","key":"10.1016\/j.yrtph.2014.10.013_b0105","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/pds.1193","article-title":"FDA drug prescribing warnings: is the black box half empty or half full?","volume":"15","author":"Wagner","year":"2006","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"1","key":"10.1016\/j.yrtph.2014.10.013_b0110","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1345\/aph.1M475","article-title":"Black box warning contraindicated comedications: concordance among three major drug interaction screening programs","volume":"44","author":"Wang","year":"2010","journal-title":"Ann. Pharmacother."},{"issue":"4","key":"10.1016\/j.yrtph.2014.10.013_b0115","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/pds.856","article-title":"What is prescription labeling communicating to doctors about hepatotoxic drugs? A study of FDA approved product labeling","volume":"13","author":"Willy","year":"2004","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"12","key":"10.1016\/j.yrtph.2014.10.013_b0120","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.2165\/11318960-000000000-00000","article-title":"Messages about black-box warnings","volume":"32","author":"Yong","year":"2009","journal-title":"Drug Saf."},{"issue":"6","key":"10.1016\/j.yrtph.2014.10.013_b0125","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.gerinurse.2008.09.005","article-title":"Black box warnings\u2014implications in practice","volume":"29","author":"Zarowitz","year":"2008","journal-title":"Geriatr. Nurs."}],"container-title":["Regulatory Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230014002530?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230014002530?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T18:08:38Z","timestamp":1565978918000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0273230014002530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S0273230014002530"],"URL":"https:\/\/doi.org\/10.1016\/j.yrtph.2014.10.013","relation":{},"ISSN":["0273-2300"],"issn-type":[{"value":"0273-2300","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An analysis of legal warnings after drug approval in Thailand","name":"articletitle","label":"Article Title"},{"value":"Regulatory Toxicology and Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yrtph.2014.10.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}